Refractory Renal Cell Carcinoma
6 clinical trials · Condition
◉ Watch Refractory Renal Cell Carcinoma
| Record | Firm | Date |
|---|---|---|
| A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma (NCT05119335) | NiKang Therapeutics, Inc. | 2021-10-26 |
| Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors (NCT02867592) | National Cancer Institute (NCI) | 2017-05-18 |
| Immunotherapy Study for Metastatic Renal Cell Cancer (NCT02035358) | NewLink Genetics Corporation | 2015-05-01 |
| Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer (NCT02298959) | National Cancer Institute (NCI) | 2015-04-08 |
Track Refractory Renal Cell Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.